The stock of Zentalis Pharmaceuticals Inc (ZNTL) has seen a -6.77% decrease in the past week, with a -19.29% drop in the past month, and a -7.07% decrease in the past quarter. The volatility ratio for the week is 9.29%, and the volatility levels for the past 30 days are at 8.46% for ZNTL. The simple moving average for the last 20 days is -9.15% for ZNTL stock, with a simple moving average of -53.68% for the last 200 days.
Is It Worth Investing in Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Right Now?
Additionally, the 36-month beta value for ZNTL is 1.86. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for ZNTL is 57.60M and currently, short sellers hold a 9.55% ratio of that float. The average trading volume of ZNTL on January 08, 2025 was 1.28M shares.
ZNTL) stock’s latest price update
The stock price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) has plunged by -5.52 when compared to previous closing price of 2.99, but the company has seen a -6.77% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-02 that SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on January 2, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 45,000 shares of the Company’s common stock to two newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
Analysts’ Opinion of ZNTL
Many brokerage firms have already submitted their reports for ZNTL stocks, with Wedbush repeating the rating for ZNTL by listing it as a “Neutral.” The predicted price for ZNTL in the upcoming period, according to Wedbush is $4 based on the research report published on August 12, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see ZNTL reach a price target of $5, previously predicting the price at $28. The rating they have provided for ZNTL stocks is “Neutral” according to the report published on June 20th, 2024.
ZNTL Trading at -14.78% from the 50-Day Moving Average
After a stumble in the market that brought ZNTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.37% of loss for the given period.
Volatility was left at 8.46%, however, over the last 30 days, the volatility rate increased by 9.29%, as shares sank -28.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.06% lower at present.
During the last 5 trading sessions, ZNTL fell by -7.59%, which changed the moving average for the period of 200-days by -79.49% in comparison to the 20-day moving average, which settled at $3.11. In addition, Zentalis Pharmaceuticals Inc saw -6.77% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZNTL starting from Lackner Mark, who sale 4,411 shares at the price of $3.12 back on Jan 02 ’25. After this action, Lackner Mark now owns 191,317 shares of Zentalis Pharmaceuticals Inc, valued at $13,762 using the latest closing price.
Diana Hausman, the Former Chief Medical Officer of Zentalis Pharmaceuticals Inc, proposed sale 9,888 shares at $2.86 during a trade that took place back on Oct 31 ’24, which means that Diana Hausman is holding shares at $28,294 based on the most recent closing price.
Stock Fundamentals for ZNTL
Current profitability levels for the company are sitting at:
- -4.91 for the present operating margin
- 0.98 for the gross margin
The net margin for Zentalis Pharmaceuticals Inc stands at -4.2. The total capital return value is set at -0.53. Equity return is now at value -42.89, with -34.60 for asset returns.
Currently, EBITDA for the company is -275.5 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 4.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.29.
Conclusion
In conclusion, Zentalis Pharmaceuticals Inc (ZNTL) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
